TP53 and invasive ductal breast carcinoma: A study of the breast cancer histopathology in TP53 carriers showed that most invasive ductal carcinomas and ductal carcinomas in situ (DCIS) in LFS are hormone receptor positive and/or HER-2 positive [34].